Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003

NCT01324947 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01324947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01324947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2011
Completion date
July 31, 2014
Enrollment
74 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma